Company intelligence / Profile preview

Alden Scientific

Ownership: Private
Development stage: Other

Overview

Alden Scientific has developed an advanced AI-powered multi-modal biological measurement system that can predict individual risk for more than 200 diseases. Their models reportedly provide up to 50-times more accurate Alzheimer’s risk assessment compared to current best estimates. The company is running IRB-approved longitudinal studies with early adopters from Silicon Valley, aiming to scale access for broader healthcare impact.

Therapeutic areas: CardiovascularEndocrinologyNeurology
Modalities: AI-powered digital biology platformMulti-omic analysisProteomicsGenomics
Industry: Digital Health Medical Devices

Partnerships

Select concierge medical practicescollaborations with leading researchers in biopharma and academia

Beyond the preview

Go deeper on Alden Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alden Scientific.

Explore the full profile